Metabolism as Information - How Cancer Turns Nutrients into Cellular Instructions

What if cancer metabolism is doing more than feeding a tumor? Emerging research shows that metabolites can act like biological messages, influencing which genes are active, whether cells remain immature or differentiate, how immune cells respond, and how tumors adapt to treatment. From mutant IDH producing an oncometabolite that reshapes cell identity to lactate and methionine altering communication within the tumor microenvironment, metabolism is becoming understood as a kind of cellular information system. The implications are striking: the future of metabolic oncology may depend not simply on cutting off cancer’s fuel supply, but on identifying and disrupting the metabolic signals that help a tumor maintain its identity, evade immune attack, and survive therapy.

The Overview

Metabolism does more than produce energy and building materials. It continuously supplies signals that help determine which genes a cell uses and what kind of cell it becomes.
Many enzymes that modify DNA and histones require metabolites such as acetyl-CoA, S-adenosylmethionine, alpha-ketoglutarate, NAD+, and oxygen. Changes in metabolism therefore change the conditions under which genes are read.
Some cancer-causing mutations create abnormal metabolites, called oncometabolites, that interfere with normal gene regulation and prevent cells from completing differentiation.
Mutant IDH is the clearest example: it produces 2-hydroxyglutarate, which alters epigenetic enzymes and cellular identity. Drugs that inhibit mutant IDH have now validated this metabolic-epigenetic pathway clinically.
Succinate and fumarate can also accumulate in particular hereditary and sporadic cancers, creating false low-oxygen signals, altering DNA and histones, and influencing neighboring immune cells.
Lactate is not merely waste from glycolysis. It functions as a fuel, signaling molecule, regulator of immunity, and source of a newer protein modification called lactylation.
The redox state of a cell - reflected in molecules such as NAD+/NADH, glutathione, and reactive oxygen species - acts as a decision system governing growth, repair, inflammation, and cell death.
Cancer cells can manipulate the information available to immune cells by consuming methionine and glucose or releasing lactate, adenosine, kynurenine, fumarate, and other suppressive metabolites.
Food affects the metabolic environment of the body, but eating a nutrient does not directly or predictably impose a particular epigenetic program on a tumor. Cellular metabolism is locally regulated and highly adaptable.
The emerging goal of metabolic oncology is not simply to starve cancer, but to identify and disrupt the specific metabolic messages and dependencies that keep a particular tumor in a malignant state.

How Metabolites Influence Gene Activity, Cell Identity, Immunity, and Treatment Response

Most people understandably think of metabolism as the process by which cells turn food into energy. Glucose, fat, and amino acids enter a series of chemical pathways, ATP is produced, and the cell receives the fuel required to function. That description is correct, but it leaves out one of the most important discoveries in modern biology: metabolism also helps tell cells what to do.

The molecules produced and consumed during metabolism are not inert leftovers. They are part of the cell's information system. Some metabolites are attached directly to proteins or DNA-associated histones. Others activate receptors, change enzyme activity, regulate oxygen sensing, alter antioxidant defenses, or determine whether portions of the genome are open or closed. The concentration, location, and movement of these molecules help a cell interpret whether nutrients are abundant, oxygen is limited, tissue has been injured, infection is present, or growth should stop.

This connection is especially important in cancer. Cancer cells do not only alter metabolism to obtain more energy. They use metabolic changes to reinforce malignant behavior. A new metabolic state can help keep a cell immature, preserve stem-like properties, suppress immune attack, support invasion, repair treatment-induced damage, or allow a temporary drug-tolerant state to become stable resistance. In some cancers, a mutation creates an abnormal metabolite that changes gene regulation across the cell. In others, ordinary metabolites accumulate in unusual amounts or appear in the wrong cellular compartment, causing normal signaling systems to produce an abnormal response.

This perspective helps move beyond the older debate over whether cancer is primarily genetic or metabolic. Genes encode enzymes and transporters that shape metabolism. Metabolites influence the enzymes that regulate genes. The tissue environment determines which nutrients and oxygen levels are available. Immune and stromal cells respond to the same metabolic conditions. Each layer feeds back into the others.

The result is not a straight line from mutation to cancer or from damaged mitochondria to cancer. It is a self-reinforcing biological state. A genetic change can produce a metabolic change. The metabolic change can reshape chromatin and cellular identity. That new identity can alter nutrient use, immune interactions, and the selection of further mutations. Cancer persists because these systems begin to support one another.

The phrase metabolism as information captures this wider view. It does not mean that nutrients contain a hidden code or that diet alone controls gene expression. It means that cells use metabolic molecules as measurable evidence of their internal and external conditions. Cancer learns to alter that evidence, misread it, or exploit the resulting instructions.

A Cell Is Always Reading Its Metabolic State

Every cell must continuously answer practical questions. Is there enough energy to divide? Are amino acids available to make proteins? Is oxygen sufficient for mitochondrial respiration? Is the DNA damaged? Is the surrounding tissue inflamed? Should the cell grow, pause, repair itself, differentiate into a specialized form, or die?

The cell does not answer these questions through one central command center. It uses overlapping sensors. The ratio of ATP to AMP reflects energy availability. Amino-acid sensors regulate mTOR, a growth-promoting complex. Oxygen-dependent enzymes influence HIF, the hypoxia-inducible factor. The NAD+/NADH ratio reflects the handling of electrons in metabolic reactions. Reactive oxygen species indicate both mitochondrial activity and cellular stress. Acetyl-CoA, S-adenosylmethionine, and alpha-ketoglutarate influence enzymes that modify chromatin.

Together, these molecules create a running biochemical description of the cell's condition. That description is imperfect and dynamic, but it is informative enough to guide behavior. When energy is scarce, AMPK can reduce energy-consuming growth programs and encourage recycling. When amino acids and growth signals are abundant, mTOR can increase protein synthesis and suppress autophagy. When oxygen falls, HIF changes the expression of genes involved in glycolysis, blood-vessel growth, iron handling, and survival.

Cancer commonly changes both the message and the reader. An oncogenic pathway may keep mTOR active despite an unstable nutrient supply. Loss of a tumor suppressor may weaken the normal response to energy stress. A metabolite may inhibit the enzyme that ordinarily removes methyl groups from DNA. A tumor may surround immune cells with adenosine or lactate, causing their metabolic sensors to interpret the environment as one in which strong attack is difficult or inappropriate.

This is one reason cancer can be so adaptive. It does not depend only on a set of abnormal genes. It can adjust how those genes are interpreted. It can shift the cellular state without waiting for a new mutation, and it can later stabilize that state through epigenetic or genetic change.

From Metabolic Fuel to Epigenetic Instruction

To understand how metabolism influences gene activity, it helps to distinguish the genetic sequence from the epigenetic system. DNA contains the sequence of letters that encodes proteins and regulatory elements. Nearly every cell in the body contains essentially the same DNA, yet a liver cell behaves differently from a neuron or an immune cell. The difference depends largely on which portions of that DNA are available for use.

DNA is wrapped around proteins called histones and organized into chromatin. Chemical modifications to DNA and histones influence how tightly that chromatin is packaged and which genes can be accessed. These modifications do not rewrite the DNA sequence. They help determine how the sequence is read.

Among the best-known modifications are acetylation and methylation. Adding acetyl groups to particular histone positions is often associated with more open chromatin and active gene expression. Methylation is more context dependent: depending on its location, it can activate or repress a gene. Enzymes add and remove these marks in carefully regulated patterns during development, immune activation, injury repair, and aging.

Many of these enzymes require metabolites. Histone acetyltransferases use acetyl-CoA as the source of acetyl groups. DNA and histone methyltransferases use S-adenosylmethionine, commonly abbreviated SAM, as the methyl donor. A large family of enzymes that remove methyl groups requires alpha-ketoglutarate, iron, and oxygen. Sirtuin deacetylases require NAD+.

Metabolism therefore influences the raw materials and operating conditions of the epigenetic system. When nutrient use changes, the availability of these metabolic cofactors can change. When a mutation causes an abnormal metabolite to accumulate, the metabolite may compete with a normal cofactor and inhibit an entire family of gene-regulating enzymes.

The important point is not that metabolism switches individual genes on and off in a simple mechanical way. Cellular compartments matter. Enzymes can produce metabolites locally in the nucleus. Different genes are affected differently depending on the chromatin proteins already present. Still, the overall principle is now well established: gene regulation is chemically connected to metabolism.

Acetyl-CoA: When Carbon Availability Reaches the Genome

Acetyl-CoA sits at a major intersection of metabolism. Cells generate it from glucose, fatty acids, acetate, and some amino acids. It can enter the citric acid cycle, contribute to fatty-acid and cholesterol synthesis, or donate acetyl groups to proteins.

Acetyl-CoA does not freely move across the inner mitochondrial membrane. When cells use glucose to support growth, mitochondria can package acetyl-derived carbon into citrate. Citrate is exported to the cytoplasm, where ATP-citrate lyase, or ACLY, converts it back into acetyl-CoA. In a foundational study, Kathryn Wellen and colleagues showed that this pathway links glucose metabolism to histone acetylation. Reducing ACLY decreased histone acetylation and altered the expression of genes involved in glucose metabolism.

This finding made an abstract connection tangible. Carbon from glucose could travel through citrate and acetyl-CoA into a chemical mark placed on histones. Growth-factor signaling could therefore increase not only glucose uptake and lipid production, but also the acetyl groups available to help establish a growth-supporting transcriptional program.

Cancer frequently activates pathways such as PI3K-AKT that increase glucose uptake, citrate production, ACLY activity, and lipid synthesis. Histone acetylation is one way this metabolic program can reinforce itself. Genes needed for nutrient transport, biosynthesis, and proliferation become more accessible, while the same pathways continue to produce the metabolites that support those chromatin states.

The relationship is not absolute. Histone acetylation depends on local enzyme activity and chromatin context, not simply on the total amount of acetyl-CoA in the cell. Tumors can also generate nuclear acetyl-CoA from acetate or other sources when oxygen or nutrients are limited. This flexibility is itself important. Cancer cells may preserve selected gene-expression programs even when one carbon source becomes scarce.

Acetyl-CoA thus illustrates a broader principle: metabolism influences gene regulation most powerfully when a cell has mechanisms to deliver a metabolite to the right place at the right time. The nucleus is not merely receiving whatever happens to remain after energy production. It contains active metabolic processes that help shape transcription.

Methionine and SAM: The Currency of Methylation

Methionine is an essential amino acid obtained from food. Inside cells, methionine is converted into S-adenosylmethionine, or SAM. SAM donates methyl groups to DNA, histones, RNA, proteins, lipids, and many small molecules. After donating a methyl group, it becomes S-adenosylhomocysteine, which can inhibit methylation reactions if it accumulates. Cells therefore regulate not only SAM but the balance between SAM and S-adenosylhomocysteine.

Experiments have shown that changing methionine metabolism can change histone methylation. In 2015, Mentch and colleagues demonstrated that methionine availability and flux through the methionine cycle altered SAM levels, histone methylation, and gene expression. This did not mean that every change in dietary methionine directly rewrites the genome. It showed that methylation reactions are connected to a nutrient-dependent metabolic network.

Cancer cells often have unusually high demand for methionine. They need it for protein synthesis, nucleotide production, polyamines, antioxidant metabolism, and extensive methylation reactions. Some cancer cells have difficulty maintaining growth when external methionine is restricted even though normal cells can recycle methionine more effectively. This phenomenon has sometimes been called methionine dependence or methionine addiction.

The informational importance of methionine becomes especially clear in the tumor microenvironment. Activated T cells also require methionine to make SAM and establish the histone methylation patterns needed for proliferation and effector function. Cancer cells can express high levels of methionine transporters and outcompete T cells for this nutrient. Bian and colleagues showed that tumor-cell expression of the transporter SLC43A2 reduced methionine and SAM in T cells, decreased an important histone methylation mark, lowered STAT5 expression, and weakened antitumor immunity. Later work showed related effects on CD4 T-cell exhaustion and PD-1 expression.

In this setting, methionine is simultaneously a nutrient, a methyl donor, and a contested resource. The tumor is not simply starving the immune cell of calories. It is limiting the immune cell's ability to maintain the epigenetic program required for attack.

This example also warns against simplistic dietary conclusions. Restricting methionine might place pressure on a methionine-dependent tumor, but it can also affect immune cells and normal tissues that require methionine. Supplementing methionine might support immune function in one context while supplying tumor metabolism in another. The relevant question is not whether methionine is good or bad. It is which cells are using it, for what purpose, and under what treatment conditions.

Alpha-Ketoglutarate: Metabolism and the Permission to Differentiate

Alpha-ketoglutarate is an intermediate of the citric acid cycle and a major point of connection between carbon and nitrogen metabolism. It can be produced from glutamine and glutamate as well as through mitochondrial oxidation. Beyond its role in energy metabolism, alpha-ketoglutarate is required by a large family of enzymes called alpha-ketoglutarate-dependent dioxygenases.

These enzymes include the TET proteins that participate in DNA demethylation, the JmjC family of histone demethylases, prolyl hydroxylases that regulate HIF, and enzymes involved in collagen maturation and DNA repair. They use alpha-ketoglutarate, oxygen, and iron to carry out their reactions. Succinate is produced as a normal product.

Because these enzymes influence DNA and histones, alpha-ketoglutarate can help connect metabolism to differentiation. Differentiation is the process by which an immature cell completes a specialized developmental program. Cancer often involves a partial loss or blockage of differentiation. Cells remain in a more flexible, proliferative, or stem-like state.

Experimental work has shown that changing alpha-ketoglutarate can influence these states. A 2019 study found that p53-mediated changes in alpha-ketoglutarate helped determine whether pancreatic cells remained capable of malignant growth or entered a more differentiated tumor-suppressive state. In colorectal cancer models, increasing alpha-ketoglutarate reduced Wnt signaling and promoted differentiation.

These studies do not establish alpha-ketoglutarate supplementation as a general cancer treatment. The metabolite may have different effects in different tissues, and delivering it to the correct cellular compartment is not simple. The importance lies in the principle: the balance of metabolites can influence whether a cancer cell remains developmentally immature or becomes more specialized and less aggressive.

Alpha-ketoglutarate also provides the backdrop for understanding oncometabolites. Several cancer-associated metabolites resemble it closely enough to interfere with the enzymes that normally use it. The result is a biochemical form of misinformation. The cell contains the enzymes needed to remove epigenetic marks, but an abnormal metabolite prevents them from working normally.

Oncometabolites: When Metabolism Sends a False Instruction

An oncometabolite is a metabolite that accumulates abnormally and helps drive malignant behavior. The term is especially useful when a specific genetic lesion changes an enzyme and produces a recognizable metabolic consequence.

The best-established oncometabolites are 2-hydroxyglutarate, succinate, and fumarate. Each is closely related to a normal citric-acid-cycle metabolite. Each can interfere with alpha-ketoglutarate-dependent enzymes. Yet their biological effects are not identical, and each occurs in a distinct genetic and tissue context.

These metabolites show why the division between genetic and metabolic theories is artificial. A mutation in a metabolic enzyme changes the metabolome. The abnormal metabolite changes chromatin, oxygen sensing, DNA repair, and immune behavior. These changes alter cell identity and selection. Genetics creates metabolism, metabolism reshapes gene regulation, and the resulting cellular state influences which additional genetic changes become advantageous.

Mutant IDH and 2-Hydroxyglutarate

Isocitrate dehydrogenase, or IDH, normally helps convert isocitrate into alpha-ketoglutarate. Recurrent mutations in IDH1 or IDH2 give the enzyme a new activity: it converts alpha-ketoglutarate into D-2-hydroxyglutarate, commonly called 2-HG.

2-HG can reach very high concentrations in IDH-mutant tumors. Because it resembles alpha-ketoglutarate, it competitively inhibits several alpha-ketoglutarate-dependent enzymes. Early studies showed that 2-HG inhibits DNA and histone demethylation pathways and creates widespread epigenetic changes. In experimental systems, mutant IDH prevented the histone demethylation required for progenitor cells to complete normal differentiation.

This produces a useful mental model. The mutation does not merely accelerate proliferation. It helps hold the cell in an abnormal developmental state. The cell retains a program that allows continued growth but has difficulty completing maturation.

IDH-mutant cancers include many lower-grade gliomas, subsets of acute myeloid leukemia, cholangiocarcinoma, chondrosarcoma, and several rarer tumors. The biological effect of IDH mutation differs among these tissues. IDH-mutant gliomas, for example, often have a more prolonged natural history than IDH-wild-type glioblastomas even though 2-HG participates in their formation. Oncometabolites do not simply make every tumor more aggressive in the same way. They create a particular disease state.

The IDH story has become the clearest clinical validation of metabolism as information. In leukemia, inhibitors of mutant IDH can lower 2-HG and allow some immature malignant cells to resume differentiation rather than killing them through conventional cytotoxicity. Enasidenib, which targets mutant IDH2, and ivosidenib, which targets mutant IDH1, received regulatory approval in defined forms of acute myeloid leukemia. Ivosidenib also improved progression-free survival in a randomized phase 3 trial in advanced IDH1-mutant cholangiocarcinoma.

The INDIGO trial extended this principle to grade 2 IDH-mutant glioma. Vorasidenib, a brain-penetrant inhibitor of mutant IDH1 and IDH2, significantly prolonged progression-free survival and delayed the need for another intervention. The FDA approved vorasidenib in August 2024 for eligible adults and children 12 years and older with grade 2 IDH-mutant astrocytoma or oligodendroglioma following surgery.

This is not merely a drug targeting a metabolic fuel. It is a drug reducing an abnormal metabolite that helps maintain a pathological cellular identity. That distinction is central to the future of metabolic oncology.

Succinate and Fumarate

Succinate dehydrogenase and fumarate hydratase are enzymes of the citric acid cycle. Inherited loss-of-function mutations in their genes can predispose people to particular cancers. Loss of succinate dehydrogenase causes succinate accumulation. Loss of fumarate hydratase causes fumarate accumulation.

Succinate and fumarate can inhibit alpha-ketoglutarate-dependent enzymes. One consequence is impaired regulation of HIF, causing cells to behave as though oxygen is limited even when oxygen is present. This is often called pseudohypoxia. Another consequence is altered DNA and histone methylation.

Fumarate can also modify cysteine residues on proteins through a reaction called succination. This can alter antioxidant systems and activate NRF2, a transcription factor that helps cells respond to oxidative and toxic stress. In fumarate hydratase-deficient cancers, a protective stress response that is normally temporary can become chronically activated.

A 2016 study showed that fumarate could act as an epigenetic modifier and promote epithelial-to-mesenchymal transition, a program associated with increased cell movement and invasion. More recent work has expanded the effect beyond the cancer cell. Fumarate released into the tumor environment can impair the activation and antitumor function of CD8 T cells.

Succinate can also function outside the cell. It can engage a cell-surface receptor called SUCNR1 and influence inflammation, blood-vessel behavior, and immune-cell recruitment. The meaning of succinate therefore depends on location. Inside mitochondria it is an ordinary metabolic intermediate. At abnormally high concentration in the cytoplasm or extracellular space, it becomes a signal.

These cancers are relatively uncommon, but they provide unusually clear examples of a broader process. Metabolic intermediates that are harmless within a controlled pathway can become pathogenic when they accumulate, move into another compartment, or persist long enough to reprogram gene expression.

Lactate: From Metabolic End Product to Signal and Chromatin Mark

Lactate has undergone one of the largest changes in scientific reputation. It was once described mainly as the waste product produced when cells lacked oxygen. It is now understood as a normal circulating fuel and a major means by which tissues exchange carbon. The heart, liver, brain, muscle, and tumors can all produce or consume lactate depending on conditions.

Cancer cells often generate large amounts of lactate through glycolysis. Monocarboxylate transporters move lactate and hydrogen ions across cell membranes. Export helps glycolytic cells regenerate NAD+ and avoid intracellular acid buildup. Other tumor cells can import lactate and oxidize it in mitochondria. Lactate therefore participates in metabolic cooperation.

Lactate also communicates. It can influence HIF signaling, blood-vessel formation, macrophage behavior, T-cell function, and extracellular acidity. High lactate and acidity can impair the ability of cytotoxic T cells and natural killer cells to perform energetically demanding antitumor functions. At the same time, some immune populations adapt to or use lactate, and the response depends on concentration, transporters, and cell type.

In 2019, researchers reported a new histone modification called histone lactylation. Lactyl groups derived from lactate-related metabolism were found on lysine residues of histones. In macrophages, the modification increased during prolonged inflammatory activation and was associated with the expression of genes involved in tissue repair.

This discovery provided a direct route from glycolysis to chromatin. A metabolite classically associated with rapid glucose breakdown could contribute to a chemical mark on histones and influence gene expression. Subsequent studies have identified lactylation on histones and many non-histone proteins in cancer, immunity, fibrosis, infection, and development. A 2024 study identified HBO1 as an enzyme capable of catalyzing lysine lactylation, adding mechanistic detail to how the mark can be written.

Cancer research has linked lactylation to angiogenesis, stemness, DNA repair, immune suppression, and therapy resistance in several experimental models. Yet this is a young field. Some lactylation may arise through more than one chemical route. The enzymes that add and remove the marks are still being defined. Many proposed disease mechanisms remain based on cell or animal studies.

The responsible conclusion is not that lactate has been proven to switch on a universal cancer program. It is that lactate can participate in gene regulation and protein function in ways that were not recognized when it was viewed merely as waste. It is both a product of the Warburg effect and one of the ways the Warburg effect can influence cellular behavior.

Redox State as Biological Information

Metabolism is fundamentally a flow of electrons. Molecules are oxidized when they lose electrons and reduced when they gain them. Cells use carriers such as NAD+/NADH and NADP+/NADPH to move those electrons between reactions.

The NAD+/NADH ratio helps determine which metabolic reactions can proceed. Glycolysis requires NAD+ to accept electrons. Mitochondrial respiration oxidizes NADH back to NAD+. When oxygen is limited or the electron transport chain is constrained, cells convert pyruvate to lactate partly to regenerate NAD+.

NAD+ is also consumed by enzymes that do not directly produce energy. PARP enzymes use it during DNA-damage signaling and repair. Sirtuins use it to remove acetyl groups from proteins, including histones and metabolic enzymes. CD38 and related enzymes use it in calcium and immune signaling. Thus, the availability of NAD+ connects energy metabolism with DNA repair, chromatin, stress responses, and inflammation.

Reactive oxygen species, or ROS, are another part of redox information. Mitochondria, NADPH oxidases, peroxisomes, and other systems generate ROS. At high levels, these molecules damage DNA, proteins, and membranes. At controlled levels, they act as signals. They can modify sensitive cysteine residues on proteins and change the activity of kinases, phosphatases, transcription factors, and ion channels.

Cancer often lives close to the edge of oxidative injury. Rapid growth, oncogenic signaling, hypoxia, mitochondrial activity, and immune attack increase ROS. Cancer cells compensate by increasing glutathione, thioredoxin, NADPH production, cystine uptake, and NRF2 signaling. These antioxidant systems do more than neutralize damage. They determine whether a cell continues proliferating, pauses for repair, undergoes apoptosis, or becomes vulnerable to ferroptosis.

NRF2 illustrates the double nature of protective pathways. In normal tissue, NRF2 helps prevent damage from toxins and oxidative stress. In established cancers, persistent NRF2 activation can support drug resistance, metabolic flexibility, iron handling, and survival. A pathway that protects healthy cells can be appropriated by malignant cells.

The same is true of antioxidants more broadly. The biological effect depends on where and when redox pressure occurs. A systemic antioxidant may protect normal tissue, alter immune behavior, or reduce a treatment-generated oxidative signal. Blocking a cancer-cell antioxidant pathway may create selective vulnerability but can also injure normal cells. The meaningful question is not whether oxidation or antioxidants are good. It is how a particular cell is using redox control to make decisions.

Nutrient Sensors Are Cellular Decision Systems

Metabolites influence gene activity not only by providing chemical groups for chromatin. They are also detected by signaling networks that coordinate the whole cell.

AMPK responds to energy stress. When ATP falls and AMP or ADP rises, AMPK is activated. It reduces energy-consuming processes such as lipid and protein synthesis and encourages energy-producing processes and autophagy. AMPK can slow growth, but under some conditions it also helps cancer cells survive temporary nutrient deprivation. A tumor suppressor and a survival mechanism can therefore be the same pathway at different stages.

mTORC1 responds to amino acids, growth factors, energy availability, and lysosomal signals. When active, it promotes protein synthesis, nucleotide production, lipid synthesis, and cell growth while suppressing autophagy. Cancer frequently activates the PI3K-AKT-mTOR network. Yet even a tumor with oncogenic mTOR signaling must still negotiate nutrient and oxygen limits.

HIF helps cells respond to oxygen scarcity. Under sufficient oxygen, alpha-ketoglutarate-dependent prolyl hydroxylases mark HIF for degradation. When oxygen is low, or when succinate, fumarate, or 2-HG interferes with these enzymes, HIF can accumulate. HIF then changes the expression of genes involved in glycolysis, glucose transport, angiogenesis, iron metabolism, pH control, and survival.

The integrated stress response detects amino-acid deficiency, endoplasmic-reticulum stress, viral signals, and heme limitation through a family of kinases that converge on the translation factor eIF2alpha. Protein synthesis is reduced globally while selected stress-response genes are increased. Cancer cells can use this program to survive treatment or nutrient deprivation.

These pathways are sometimes presented as switches, but they behave more like negotiating systems. AMPK can restrain mTOR, but both can be active in different compartments or times. HIF can increase glycolysis while mitochondria remain important. Autophagy can suppress early tumor formation by removing damaged components yet later sustain an established cancer during stress.

Cancer succeeds partly because it uncouples these decision systems from their normal tissue purpose. Growth signaling remains active when growth should stop. Stress responses become chronic survival programs. Signals designed to promote temporary repair are used to maintain malignant persistence.

The Tumor Microenvironment Receives Metabolic Messages

A tumor's metabolites do not remain inside cancer cells. They move through extracellular fluid, blood vessels, cell-cell contacts, and vesicles. Neighboring immune cells, fibroblasts, endothelial cells, and nerves possess receptors and metabolic enzymes that interpret these molecules.

This means a tumor can regulate surrounding cells without using a conventional protein growth factor. It can change the concentration of oxygen, glucose, amino acids, lactate, potassium, adenosine, tryptophan metabolites, succinate, fumarate, lipids, and reactive molecules. Each change alters the information received by nearby cells.

The effect is especially important for immunity. Activated T cells must rapidly increase glycolysis, mitochondrial function, amino-acid uptake, nucleotide synthesis, and epigenetic remodeling. They are not passive soldiers that merely need to recognize a tumor antigen. They must build a complete metabolic program to divide and kill.

Cancer cells can interfere at each step. They consume glucose and methionine. They release lactate and acid. Hypoxic cells and regulatory immune cells convert ATP into adenosine through CD39 and CD73. Adenosine activates A2A and A2B receptors and raises cyclic AMP, suppressing T-cell and natural-killer-cell function. Genetic deletion of the A2A receptor has improved CAR T-cell activity in experimental models, and newer work suggests that adenosine can also enter activated T cells and directly disrupt nucleotide synthesis.

Tryptophan metabolism creates another set of signals. Enzymes such as IDO1, TDO2, and IL4I1 generate metabolites that activate the aryl hydrocarbon receptor, or AHR. AHR is a ligand-activated transcription factor that influences immune differentiation, barrier tissues, and responses to environmental compounds. In tumors, AHR activation by tryptophan-derived metabolites can promote regulatory or dysfunctional immune states. IL4I1 was identified as a metabolic immune checkpoint that generates AHR-activating metabolites and suppresses antitumor immunity [13]. Microbial tryptophan metabolites can also activate AHR in tumor-associated macrophages and reduce immune attack.

Fumarate, succinate, and 2-HG likewise affect immune cells. Tumor-derived fumarate can interfere with T-cell receptor signaling. D-2-HG can enter T cells and alter their metabolism and function. The metabolic identity of the cancer cell therefore becomes part of the immune landscape.

This is a deeper form of immune evasion than hiding an antigen. The tumor changes the biochemical conditions under which immune recognition must operate. An exhausted T cell may still recognize the cancer but lack the metabolic and epigenetic capacity to sustain an attack.

Metabolic Competition Can Rewrite Immune-Cell Identity

The methionine studies demonstrate how nutrient competition becomes gene regulation. When cancer cells remove methionine from the local environment, T cells lose SAM and histone methylation marks needed to maintain effector genes. This can reduce survival, alter checkpoint expression, and encourage exhaustion.

Glucose competition can produce related effects. Activated T cells require glycolysis for cytokine production and rapid expansion. Low glucose and high lactate reduce their ability to make interferon-gamma and perform cytotoxic functions. By contrast, regulatory T cells and some tumor-associated macrophages may tolerate or exploit conditions that inhibit cytotoxic lymphocytes.

The immune system is therefore not uniformly helped by one metabolic intervention. Inhibiting glycolysis might weaken a glycolytic tumor but also impair newly activated T cells. Restricting methionine may stress cancer cells while disturbing methylation in immune cells. Blocking adenosine signaling may restore immunity without depriving cells of a basic nutrient.

This is why immunometabolism has become central to treatment design. The target is not merely the cancer's consumption of a nutrient. It is the unequal effect of the metabolic environment on malignant and immune cells. Successful therapy may need to reduce a suppressive metabolite, protect immune-cell nutrient access, or engineer immune cells to function under hostile conditions.

Metabolism Helps Establish Cell Identity and Memory

Cells can change behavior quickly through signaling and more slowly through epigenetic memory. Metabolism participates in both. A brief nutrient shortage may activate AMPK within minutes. If the stress persists, changes in chromatin can stabilize a new transcriptional program. If that program provides a survival advantage, the cells carrying it may dominate after treatment.

Cancer stem-like states are one example. These states are not always a permanently distinct population. Some cancer cells can enter or leave stem-like programs depending on hypoxia, inflammatory signals, mitochondrial function, and metabolite availability. Alpha-ketoglutarate-dependent enzymes, acetyl-CoA production, methionine metabolism, and redox balance can all influence the chromatin landscape associated with stemness.

Epithelial-to-mesenchymal transition is another example. During this transition, cells lose some epithelial characteristics and acquire greater motility, stress resistance, and plasticity. Fumarate, lactate-related signaling, and changes in acetyl-CoA and redox state can support aspects of this program. The transition is rarely all-or-none; many tumor cells occupy hybrid states.

Treatment can create drug-tolerant persister cells. These cells survive therapy without necessarily having a permanent resistance mutation. They may slow proliferation, increase autophagy, strengthen antioxidant defenses, alter lipid metabolism, or depend more heavily on mitochondria. Epigenetic remodeling helps maintain the state long enough for stable resistance to emerge.

This suggests that metabolic information can function as a bridge between temporary adaptation and durable evolution. A cell experiences stress, changes metabolism, uses that metabolic state to alter transcription and chromatin, survives, and later acquires genetic changes that make the adaptation permanent.

The therapeutic opportunity is to interrupt the bridge. A drug-tolerant state may be more dependent than the original tumor on oxidative phosphorylation, GPX4, NADPH, autophagy, or an amino-acid pathway. Sequential treatment could first force the tumor into a constrained state and then target the new dependency.

Metabolic Information Is Local, Compartmentalized, and Time-Dependent

One of the most important refinements in this field is that the total amount of a metabolite in a cell may not reveal what it is doing. Metabolism is compartmentalized.

Mitochondria, cytoplasm, nucleus, lysosomes, peroxisomes, and the extracellular space can contain different concentrations of the same metabolite. Acetyl-CoA generated near chromatin may influence histone acetylation even if total cellular acetyl-CoA changes little. NAD+ can be regulated in nuclear, mitochondrial, and cytoplasmic pools. Lactate outside the cell can signal through receptors or change pH, while lactate-derived carbon inside the cell can enter metabolism or protein modifications.

Timing matters as well. A brief rise in ROS can activate an adaptive response. Persistent ROS can damage DNA and select for antioxidant defenses. Temporary histone acetylation may allow a stress-response gene to be expressed. Repeated stress can create a more stable chromatin state.

This is one reason blood measurements cannot fully describe tumor metabolism. Plasma glucose, ketones, amino acids, or lactate provide information about the whole body, but the concentrations experienced by cells deep within a tumor may be very different. Blood vessels are uneven. Some regions are hypoxic and acidic. Others are well perfused. Cancer cells beside an adipocyte receive different resources from cells beside a necrotic region.

The same caution applies to tumor biopsies. A tissue sample captures one location at one time. It may miss a metabolically distinct population elsewhere. New spatial metabolomics, isotope tracing, imaging, and single-cell methods are beginning to map these local differences.

The future of metabolism-as-information research will depend on measuring not only which metabolites are present, but where they are produced, which cells receive them, and how the pattern changes during treatment.

Therapy Can Change the Message

Every cancer treatment changes metabolism. Surgery alters inflammation and nutrient supply. Radiation generates reactive oxygen species and damages mitochondria and DNA. Chemotherapy changes proliferation, repair demands, and tissue turnover. Targeted therapy blocks signaling pathways that normally control nutrient uptake and biosynthesis. Immunotherapy increases the metabolic demands placed on T cells.

Sometimes these changes contribute directly to effectiveness. Radiation creates oxidative and DNA damage that overwhelms repair. Antimetabolite chemotherapy interferes with nucleotide synthesis. Asparaginase depletes an amino acid that particular leukemias cannot adequately produce. IDH inhibitors reduce an oncometabolite and permit differentiation.

Treatment can also produce unwanted metabolic messages. Dying cells release ATP, nucleotides, amino acids, lipids, and cellular debris. ATP may initially promote immune activation, but extracellular enzymes can convert it to immunosuppressive adenosine. Hypoxia may increase if blood vessels are damaged. Surviving cells may activate NRF2, autophagy, or the integrated stress response.

The same treatment may therefore create both pro-immune and suppressive signals. The outcome depends on dose, timing, tissue, and which populations survive.

An important future strategy is to design combinations around these treatment-induced states. Radiation or chemotherapy may increase dependence on antioxidant defense. Targeted therapy may create a slow-cycling mitochondrial state. Checkpoint blockade may work better when adenosine or lactate suppression is relieved. IDH inhibition may change differentiation and immune recognition in ways that affect subsequent therapy.

This approach is different from adding a general metabolic supplement to standard treatment. It begins with a measurable treatment-induced change and asks whether that change creates a selective vulnerability or restores a blocked biological program.

Precision Metabolic Oncology: Targeting the Instruction, Not Just the Fuel

The most successful metabolic cancer therapies are usually precise. They do not simply reduce energy. They target a metabolic feature that is unusually important to a defined tumor.

Mutant IDH is the leading example because the chain of causation is unusually clear. A mutation creates a new enzyme activity. The enzyme produces 2-HG. The metabolite alters epigenetic enzymes and differentiation. A drug blocks the mutant enzyme, reduces 2-HG, and produces clinical benefit in patients whose tumors carry the mutation.

Other established therapies also fit the wider metabolic framework. Antifolates and fluoropyrimidines interfere with nucleotide metabolism. Asparaginase exploits the limited ability of certain leukemias to synthesize asparagine. Hormonal therapies alter systemic and cellular metabolism as well as receptor signaling. mTOR inhibitors affect nutrient-driven growth programs.

The next generation may target metabolite transporters, redox systems, methionine or serine pathways, lactate exchange, adenosine signaling, NAD synthesis, ferroptosis protection, or the enzymes that write and erase newer acyl modifications. Yet a mechanistically attractive target is not enough.

A clinically useful metabolic target must be important in the actual human tumor, not only in nutrient-rich cell culture. Normal tissues must have a therapeutic advantage. The cancer should not easily obtain the metabolite from neighboring cells or switch to another pathway. A biomarker should identify the relevant patients. The drug must reach the right compartment.

The IDH experience also teaches that metabolic therapy may work by changing cell state rather than rapidly shrinking a tumor. Differentiation, delayed progression, restored immune function, and prevention of resistance may be meaningful endpoints. Metabolic oncology may therefore require different expectations from traditional cytotoxic treatment.

What This Perspective Means for Diet and Supplements

The idea that metabolites influence gene expression naturally raises questions about diet. Food supplies the carbon, nitrogen, vitamins, minerals, and cofactors from which metabolism is built. Obesity, insulin resistance, muscle mass, liver function, microbiome activity, and inflammation all influence the systemic metabolic environment. Diet therefore matters.

The mistake is to assume a direct one-to-one relationship between eating a substance and changing a specific tumor mark. Consuming acetate does not predictably acetylate tumor histones. Eating more or less methionine does not uniformly raise or lower methylation across the cancer genome. Taking alpha-ketoglutarate does not guarantee that it will enter the tumor nucleus, reach the relevant enzyme, or promote differentiation. Raising NAD+ systemically may affect normal and malignant cells in different ways.

Cells regulate transport, synthesis, breakdown, compartmentalization, and feedback. The liver and other organs buffer many dietary changes. Tumors can obtain nutrients from surrounding cells or recycle internal components. The immune system may depend on the same nutrient being restricted.

This does not make dietary research unimportant. It changes the quality of the question. Instead of asking whether a food turns a cancer gene on or off, research can ask whether a defined dietary intervention changes insulin, amino-acid availability, body composition, drug exposure, immune function, or a measured tumor metabolite in a particular clinical setting.

Methionine restriction, ketogenic diets, fasting, protein modification, and serine or glycine restriction have all produced interesting preclinical findings. Human trials must account for cancer type, treatment, nutritional status, weight loss, metabolic health, and immune effects. A well-nourished patient with insulin resistance presents a different biological problem from an underweight patient with muscle loss.

Supplements require the same discipline. A compound may alter AMPK, NRF2, histone enzymes, or redox systems in cells at concentrations that are not achieved safely in people. A molecule described as an antioxidant can become pro-oxidant under other conditions. An intervention that protects normal tissue can also protect cancer cells from treatment.

The metabolism-as-information framework supports nutritional and integrative thinking, but it argues for greater precision rather than broader claims. Diet is part of the whole-body environment in which a tumor lives. It is not a remote control for individual epigenetic marks.

How This Refines the Metabolic Theory of Cancer

The classic metabolic theory emphasized impaired mitochondrial respiration and compensatory fermentation. That framework restored deserved attention to the Warburg effect and to the possibility that metabolic dysfunction can drive genetic instability and malignant behavior.

The information perspective broadens the theory in several ways. First, metabolism influences cancer even when mitochondria remain functional. A tumor can use mitochondrial metabolism to produce alpha-ketoglutarate, citrate, aspartate, NADPH, and other molecules needed for gene regulation and growth.

Second, the significance of glycolysis extends beyond ATP. Glycolysis changes NAD+/NADH balance, produces biosynthetic intermediates, supports lactate export, alters acidity, and contributes to lactylation and immune suppression.

Third, metabolic abnormalities need not begin with damaged respiration. A mutation in IDH, SDH, or FH can create an oncometabolite. Growth-factor signaling can increase acetyl-CoA and histone acetylation. Inflammation and hypoxia can reprogram nutrient use. The initiating event varies.

Fourth, cancer metabolism is not confined to the cancer cell. Methionine competition changes T-cell chromatin. Adenosine changes immune signaling. Fumarate alters T-cell activation. Microbial metabolites affect macrophages. The metabolic theory becomes a theory of communication within a tissue ecosystem.

Finally, metabolism can preserve malignant identity. Cancer is not only uncontrolled growth. It is a failure of normal developmental and tissue constraints. Oncometabolites, chromatin cofactors, redox programs, and nutrient sensors can keep cells in a state that remains adaptable, immature, and resistant to correction.

The strongest modern version of the metabolic theory is therefore not that defective mitochondria are the sole cause of cancer. It is that altered metabolic organization is one of the principal ways cancer establishes and maintains its identity. Metabolism supplies energy, matter, and information simultaneously.

Questions the Field Is Now Trying to Answer

Several questions are likely to shape the next phase of research.

Researchers need better measurements of metabolites in living human tumors. Stable-isotope tracing, magnetic-resonance spectroscopy, positron-emission imaging, spatial metabolomics, and single-cell methods can reveal which nutrients actually reach a tumor and how they are used.

The field must determine which epigenetic changes are caused directly by metabolites and which merely accompany a changing cell state. Histone lactylation is a good example. The modification is real, but its writers, erasers, sources, and functional importance must be established separately in each disease context.

Metabolic compartments need to be mapped. Nuclear acetyl-CoA or NAD+ may matter more for gene regulation than the total cellular concentration. Extracellular lactate, adenosine, or succinate may signal differently from the same molecule inside mitochondria.

The relationship between metabolic therapy and immunity requires particular attention. Restricting a nutrient may harm tumor cells and T cells together. The best intervention may target a transporter used disproportionately by the tumor, remove a suppressive waste product, or engineer immune cells to resist the environment.

Researchers also need to understand metabolic memory. Which treatment-induced states disappear when therapy stops? Which are maintained through chromatin? Which create a window for sequential treatment before permanent resistance develops?

Finally, clinical trials will need stronger biomarkers. A tumor's mutation may predict an oncometabolite, as with IDH, but most metabolic dependencies are less obvious. Combining genomic, transcriptomic, proteomic, metabolomic, and imaging information may be necessary to identify the patients most likely to benefit.

Metabolism is often described as the cell's economy: the system that obtains resources, produces energy, and builds new material. That description is incomplete. Metabolism is also part of the cell's language.

Acetyl-CoA supplies acetyl groups that help regulate chromatin. Methionine becomes SAM, the major methyl donor. Alpha-ketoglutarate permits enzymes to remove epigenetic marks and regulate oxygen sensing. NAD+ connects electron flow with DNA repair and deacetylation. Lactate can move between cells, suppress immunity, and contribute to protein lactylation. Succinate, fumarate, and 2-hydroxyglutarate can become false signals that alter differentiation and gene expression.

Cancer exploits these connections. It changes nutrient uptake, enzyme activity, redox balance, metabolite location, and communication with neighboring cells. These changes help the tumor maintain a malignant identity, adapt to treatment, and weaken immune attack.

The clinical success of mutant-IDH inhibitors shows that this is more than an elegant theory. A mutation can create an abnormal metabolite; the metabolite can maintain a pathological epigenetic state; and blocking its production can benefit patients. That is one of the clearest demonstrations that cancer metabolism can be treated at the level of information.

Most tumors will be more complicated. They will not depend on one oncometabolite or one enzyme. Their metabolic messages will vary by region and change during treatment. Diet, the microbiome, immune cells, and whole-body metabolism will influence the system without controlling it completely.

The goal is therefore not to reduce cancer to metabolism. It is to recognize that metabolism is one of the principal ways genes, environment, cell identity, and tissue behavior are joined together.

Cancer turns nutrients into fuel and building material, but it also turns them into instructions. Learning to identify and interrupt the instructions that sustain malignancy may become one of the most precise and powerful forms of metabolic therapy.